In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.

MLA

Whitehead, Stephen S., et al. “In a Randomized Trial, the Live Attenuated Tetravalent Dengue Vaccine TV003 Is Well-Tolerated and Highly Immunogenic in Subjects with Flavivirus Exposure Prior to Vaccination.” PLoS Neglected Tropical Diseases, vol. 11, no. 5, May 2017, p. e0005584. EBSCOhost, https://doi.org/10.1371/journal.pntd.0005584.

APA

Whitehead, S. S., Durbin, A. P., Pierce, K. K., Elwood, D., McElvany, B. D., Fraser, E. A., Carmolli, M. P., Tibery, C. M., Hynes, N. A., Jo, M., Lovchik, J. M., Larsson, C. J., Doty, E. A., Dickson, D. M., Luke, C. J., Subbarao, K., Diehl, S. A., & Kirkpatrick, B. D. (2017). In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination. PLoS Neglected Tropical Diseases, 11(5), e0005584. https://doi.org/10.1371/journal.pntd.0005584

Chicago

Whitehead, Stephen S, Anna P Durbin, Kristen K Pierce, Dan Elwood, Benjamin D McElvany, Ellen A Fraser, Marya P Carmolli, et al. 2017. “In a Randomized Trial, the Live Attenuated Tetravalent Dengue Vaccine TV003 Is Well-Tolerated and Highly Immunogenic in Subjects with Flavivirus Exposure Prior to Vaccination.” PLoS Neglected Tropical Diseases 11 (5): e0005584. doi:10.1371/journal.pntd.0005584.